Cytosorbents Corporation (NASDAQ:CTSO) Q2 2020 Earnings Conference Call August 4, 2020 4:45 PM ET Company Representatives Phillip Chan - Chief Executive Officer Vincent Capponi - Chief Operating Officer Kathleen Bloch - Chief Financial Officer Efthymios Deliargyris - Chief Medical Officer Christian Steiner - Senior Vice President of Sales and Marketing from Germany Christopher Cramer - Vice President of Business Development Jeremy Feffer - LifeSci Advisors, Investor Relations Conference Call Participants An ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 Or ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36792 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 98-0373793 (State or other jurisdiction of (I.R.S. Employer ...

Cytosorbents Corporation (NASDAQ:CTSO) Q1 2020 Results Earnings Conference Call May 5, 2020 4:40 PM ET Company Participants Jeremy Feffer - IR, LifeSci Advisors Phillip Chan - CEO and President Kathleen Bloch - CFO Ethymios Deliargyris - CMO Christian Steiner - Senior Vice President of Sales and Marketing from Germany Christopher Cramer - Vice President of Business Development. Vincent Capponi - COO Conference Call Participants Andrew D'Silva - B. Riley & Company Sean Lee - H.C. Wainwright Operator Good aft ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36792 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 98-0373793 (State or other jurisdiction of (I.R.S. Employer Identification No ...

CytoSorbents Corporation (NASDAQ:CTSO) Q4 2019 Earnings Conference Call March 5, 2020 4:45 PM ET Company Participants Jeremy Feffer - IR, LifeSci Advisors Phillip Chan - CEO and President Kathleen Bloch - CFO Vincent Capponi - COO Conference Call Participants Andrew D'Silva - B. Riley FBR Company Sean Lee - H.C. Wainwright Operator Good afternoon and welcome to the CytoSorbents' 2019 Financial and Operating Results Conference Call. At this time, all participants are in a listen-only mode. Following the form ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-36792 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 98-0373793 (State or other jurisdiction of incorporation or (I.R.S. Emp ...

Cytosorbents Corporation (NASDAQ:CTSO) Q3 2019 Earnings Conference Call November 5, 2019 4:45 PM ET Company Participants Jeremy Feffer - Investor Relations, LifeSci Advisors Phillip Chan - Chief Executive Officer and President Kathleen Bloch - Chief Financial Officer Vincent Capponi - Chief Operating Officer Eric Mortensen - Chief Medical Officer Conference Call Participants Josh Jennings - Cowen & Company Andrew D'Silva - B. Riley FBR Sean Lee - H.C. Wainwright Michael Okunewitch - Maxim Group Jason Kolber ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36792 CYTOSORBENTS CORPORATION (Exact name of registrant as specified in its charter) Delaware 98-0373793 (State or other jurisdiction of (I.R.S. Employer Identificatio ...

HELPING REDUCE DEADLY UNCONTROLLED INFLAMMATION IN HOSPITALIZED PATIENTS WORLDWIDE NASDAQ: CTSO Investor Presentation October 2019 Safe Harbor Statement This presentation contains "forward-looking statements" pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "intend ...

Cytosorbents Corporation (NASDAQ:CTSO) Q2 2019 Results Earnings Conference Call August 6, 2019 4:45 PM ET Company Participants Jeremy Feffer - IR, LifeSci Advisors Phillip Chan - CEO and President Kathleen Bloch - CFO Vincent Capponi - COO Christopher Cramer - VP of Business Development Christian Steiner - VP of Sales and Marketing Eric Mortensen - Chief Medical Officer Conference Call Participants Josh Jennings - Cowen & Company Andrew D'Silva - B. Riley Jason McCarthy - Maxim Group Jason Kolbert - Dawson ...